Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment

Kimura,Michio; Yamada,Shiori; Go,Makiko; Yasuda,Satoshi; Toyoda,Hidenori; Usami,Eiseki

doi:10.3892/ol.2024.14464

Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment

Authors:
- Michio Kimura
- Shiori Yamada
- Makiko Go
- Satoshi Yasuda
- Hidenori Toyoda
- Eiseki Usami
View Affiliations

Affiliations: Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503‑8502, Japan, Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Gifu 503‑8502, Japan
Published online on: May 17, 2024 https://doi.org/10.3892/ol.2024.14464
Article Number: 330

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atezolizumab plus bevacizumab (Atez/BV) as first‑line therapy and lenvatinib (LEN) as second‑line therapy are the recommended treatments for patients with unresectable hepatocellular carcinoma. Adverse immune events caused by immune checkpoint inhibitors (such as Atez) generally only occur several months after administration; therefore, the potential influence of the first‑line treatment on second‑line treatment is not clear. The present study investigated the safety of second‑line LEN treatment (2nd LEN) by comparing the adverse events (AEs) of 2nd LEN after first‑line Atez/BV treatment for unresectable liver cancer, with those of first‑line LEN treatment (1st LEN). Patients who received Atez/BV as first‑line therapy and 2nd LEN, or those who received 1st LEN at Ogaki Municipal Hospital (Ogaki, Japan) between April 2018 and September 2023 were retrospectively evaluated for treatment duration and AEs. The median treatment duration for patients in the 1st LEN (n=39) and 2nd LEN (n=13) groups was 151.0 days [95% confidence interval (CI) 77‑303 days] and 128.5 days (95% CI 68‑270 days), respectively (P=0.385). A greater proportion of patients showed elevated aspartate aminotransferase/alanine aminotransferase levels in the 2nd LEN group (76.9%) compared with those in the 1st LEN group (46.2%) (P=0.016). Hypothyroidism was more common in those receiving 2nd LEN (46.2%) than 1st LEN (12.8%) (P=0.016). In addition, grade 1 (three patients) and grade 2 (three patients) hypothyroidism was observed in patients receiving 2nd LEN. For these six patients, during first‑line Atez/BV treatment, four patients had grade 0 hypothyroidism and two patients had grade 1 hypothyroidism (P=0.025). In conclusion, patients receiving 2nd LEN after treatment with Atez/BV are at an increased risk of hypothyroidism.

View Figures

View References

1	Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 14:1894–1905. 2020. View Article : Google Scholar
2	Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, et al: Systemic therapy and sequencing options in advanced hepatocellular carcinoma: A systematic review and network meta-analysis. JAMA Oncol. 6:e2049302020. View Article : Google Scholar : PubMed/NCBI
3	Takeda S, Namisaki T, Tsuji Y, Fujimoto Y, Murata K, Enomoto M, Fujinaga Y, Nishimura N, Kitagawa K, Takaya H, et al: Initial experience with atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma: A real-world retrospective study. Anticancer Res. 42:5465–5473. 2022. View Article : Google Scholar : PubMed/NCBI
4	Kobayashi K, Nagai H, Matsui T, Matsuda T and Higai K: Importance of Atezolizumab plus bevacizumab combination treatment as first-line therapy for immunological changes in patients with unresectable hepatocellular carcinoma. Anticancer Res. 43:4601–4609. 2023. View Article : Google Scholar : PubMed/NCBI
5	Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M and Funahashi Y: Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014:6387472014. View Article : Google Scholar : PubMed/NCBI
6	Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 24:1163–1173. 2018. View Article : Google Scholar
7	Ogushi K, Chuma M, Uojima H, Hidaka H, Numata K, Kobayashi S, Hirose S, Hattori N, Fujikawa T, Nakazawa T, et al: Safety and Efficacy of lenvatinib treatment in Child-Pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice: A multicenter analysis. Clin Exp Gastroenterol. 13:385–396. 2020. View Article : Google Scholar : PubMed/NCBI
8	Iwamoto H, Suzuki H, Shimose S, Niizeki T, Nakano M, Shirono T, Okamura S, Noda Y, Kamachi N, Nakamura T, et al: weekends-off lenvatinib for unresectable hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events. Cancers (Basel). 12:10102020. View Article : Google Scholar : PubMed/NCBI
9	Yoo C, Kim JH, Ryu MH, Park SR, Lee D, Kim KM, Shim JH, Lim YS, Lee HC, Lee J, et al: Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational multicenter retrospective study. Liver Cancer. 10:107–114. 2021. View Article : Google Scholar : PubMed/NCBI
10	Aoki T, Kudo M, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Tsurusaki M and Nishida N: Exploratory analysis of lenvatinib therapy in patients with unresectable hepatocellular carcinoma who have failed prior PD-1/PD-L1 checkpoint blockade. Cancers (Basel). 12:30482020. View Article : Google Scholar : PubMed/NCBI
11	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, et al: Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma: Clinical results show importance of hepatic reserve function. Oncology. 101:624–633. 2023. View Article : Google Scholar : PubMed/NCBI
12	National Cancer Institute, . US Department Of Health And Human Services: Common terminology criteria for adverse events (CTCAE). Version 5.0, 2017. https://ctepCancer. Gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5×11.pdf
13	Tamai T, Hayato S, Hojo S, Suzuki T, Okusaka T, Ikeda K and Kumada H: Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses. J Clin Pharmacol. 57:1138–1147. 2017. View Article : Google Scholar : PubMed/NCBI
14	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
15	Lee SE, Kim KA, Lee H and Park J: Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors. Cancer Epidemiol. 81:1022652022. View Article : Google Scholar : PubMed/NCBI
16	Makita N and Iiri T: Tyrosine kinase inhibitor-induced thyroid disorders: A review and hypothesis. Thyroid. 23:151–159. 2013. View Article : Google Scholar : PubMed/NCBI
17	Ahmadieh H and Salti I: Tyrosine kinase inhibitors induced thyroid dysfunction: A review of its incidence, pathophysiology, clinical relevance, and treatment. Biomed Res Int. 2013:7254102013. View Article : Google Scholar : PubMed/NCBI
18	Muto H, Kuzuya T, Kawabe N, Ohno E, Funasaka K, Nagasaka M, Nakagawa Y, Miyahara R, Shibata T, Hashimoto S, et al: Clinical outcomes with lenvatinib in patients previously treated with atezolizumab/bevacizumab for advanced hepatocellular carcinoma. Anticancer Res. 43:4673–4682. 2023. View Article : Google Scholar : PubMed/NCBI
19	Otsubo K, Nakatomi K, Furukawa R, Ashida K, Yoneshima Y, Nakanishi Y and Okamoto I: Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab. Ann Oncol. 28:3106–3107. 2017. View Article : Google Scholar : PubMed/NCBI
20	Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VHM and Menzies AM: Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab. 18:e3704–e3713. 2021. View Article : Google Scholar : PubMed/NCBI
21	Ichimura T, Ichikura D, Hinata M, Hida N and Baba T: Thyroid dysfunction with atezolizumab plus bevacizumab after Lenvatinib in hepatocellular carcinoma: A case series. SAGE Open Med Case Rep. 11:2050313X2311644882023.PubMed/NCBI